Glenmark Pharmaceuticals announces product approval for Ryaltris(R) in Australia

Glenmark receives ANDA approval for Metformin Hydrochloride Extended-Release Tablets USP, 500 mg and 1000 mg

Glenmark’s consolidated revenue rises 9.05% to Rs. 28,150.4 Mn. in Q2 FY 2019-20

Glenmark Pharmaceuticals receives ANDA approval for Adapalene and Benzoyl Peroxide Gel, 0.1%|2.5%

Glenmark Pharmaceuticals receives ANDA approval for Abiraterone Acetate Tablets USP, 250 mg

Glenmark Pharmaceuticals receives tentative ANDA approval for Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg

Glenmark receives approval from Russian Ministry of Healthcare to market Montlezir (Levocetirizine+Montelukast) film-coated tablets

Glenmark Pharmaceuticals secures its position in the prestigious Dow Jones Sustainability Emerging Markets Index for the second year in a row

Glenmark Receives Orphan Drug Designation for GBR 1342, a Bispecific Antibody Candidate Under Evaluation for the Treatment of Multiple Myeloma

Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Foam, 0.05%

Glenmark Pharmaceuticals receives ANDA approval for Pimecrolimus Cream, 1%

Glenmark Pharmaceuticals receives ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)

Glenmark receives approval for combination of Remogliflozin Etabonate and Metformin Hydrochloride for adults with type 2 diabetes in India

Glenmark’s consolidated revenue at Rs. 23,228.79 Mn. for Q1 FY 2019 – 20

Glenmark & Torrent sign licensing agreement for co-marketing of Remogliflozin Etabonate in India

Glenmark Pharmaceuticals receives ANDA approval for Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg

Glenmark Pharmaceuticals receives ANDA approval for Ezetimibe and Simvastatin Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg

Glenmark to partner with Novartis to promote, commercialize and distribute three respiratory products in Brazil

Glenmark Pharmaceuticals receives tentative ANDA approval for Clindamycin Phosphate Foam, 1%

Glenmark’s consolidated revenue rises 12.44% to Rs. 25,634.74 Mn. for Q4 FY 2018-19

Glenmark Pharmaceuticals receives ANDA approval for Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg

Glenmark Pharmaceuticals receives ANDA approval for Solifenacin Succinate Tablets, 5 mg and 10 mg

Glenmark Pharmaceuticals receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg

Glenmark Pharmaceuticals Announces Results from a Phase 3 Study of Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, in Patients Aged 6 to Under 12 Years

Glenmark appoints Dr. Yasir Rawjee as Chief Executive Officer of Glenmark Life Sciences, its subsidiary for the API business

Glenmark Therapeutics Expands Specialty Portfolio with OTIPRIO® Co-Promotion Agreement in the U.S. with Otonomy for Acute Otitis Externa Indication

Glenmark launches novel, globally-researched anti-diabetes drug Remogliflozin in India

Glenmark receives approval from Russian Ministry of Healthcare to market Momate Rhino metered nasal spray as an Over-the-Counter (OTC) product

Glenmark Pharmaceuticals receives ANDA approval for Clindamycin and Benzoyl Peroxide Gel, 1%|5%

Glenmark Announces Appointment of Alessandro Riva as CEO of its New Innovation Company